CD19 and leukemia: It was found that N125 low glycosylation of CD19 would lead to the loss of protein expression, which seriously impaired the efficacy of CAR-T cells against leukemia, and N125 high glycosylation of CD19 would prevent the activity of CAR-T, thus making CAR-T treatment resistant.